Can an immune-regulatory vaccine prevent HIV infection?

References

• Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol.8(4), 247–258 (2008).
   PubMed Web of Science ®Google Scholar
• Johnston MI, Fauci AS. An HIV vaccine – challenges and prospects. N. Engl. J. Med.359(9), 888–890 (2008).
   PubMed Web of Science ®Google Scholar
• Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat. Med.15(8), 866–870 (2009).
   PubMed Web of Science ®Google Scholar
• Walker LM, Burton DR. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr. Opin. Immunol.22(3), 358–366 (2010).
   PubMed Web of Science ®Google Scholar
• Buchbinder SP, Mehrotra DV, Duerr A et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet372(9653), 1881–1893 (2008).
   PubMed Web of Science ®Google Scholar
• HIV vaccine failure prompts Merck to halt trial. Nature449 (2007).
   PubMedGoogle Scholar
• Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med.361(23), 2209–2220 (2009).
   PubMed Web of Science ®Google Scholar
• Douek DC, Brenchley JM, Betts MR et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature417(6884), 95–98 (2002).
   PubMed Web of Science ®Google Scholar
• Rosa DS, Ribeiro SP, Almeida RR et al. A DNA vaccine encoding multiple HIV CD4 epitopes elicits vigorous polyfunctional, long-lived CD4+ and CD8+ T cell responses. PLoS One6(2), e16921 (2011).
   PubMed Web of Science ®Google Scholar
• van Asten L, Danisman F, Otto SA et al. Pre-seroconversion immune status predicts the rate of CD4 T cell decline following HIV infection. AIDS18(14), 1885–1893 (2004).
   PubMed Web of Science ®Google Scholar
• Deeks SG, Kitchen CM, Liu L et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood104(4), 942–947 (2004).
   PubMed Web of Science ®Google Scholar
• Hazenberg MD, Otto SA, van Benthem BH et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS17(13), 1881–1888 (2003).
   PubMed Web of Science ®Google Scholar
• Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z, Victorino RM. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J. Immunol.169(6), 3400–3406 (2002).
   PubMed Web of Science ®Google Scholar
• Naicker DD, Werner L, Kormuth E et al. Interleukin-10 promoter polymorphisms influence HIV-1 susceptibility and primary HIV-1 pathogenesis. J. Infect. Dis.200(3), 448–452 (2009).
   PubMedGoogle Scholar
• Shin HD, Winkler C, Stephens JC et al. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc. Natl Acad. Sci. USA97(26), 14467–14472 (2000).
   PubMed Web of Science ®Google Scholar
• Hansen SG, Ford JC, Lewis MS et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature473(7348), 523–527 (2011).
   PubMed Web of Science ®Google Scholar
• Wilson NA, Keele BF, Reed JS et al. Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J. Virol.83(13), 6508–6521 (2009).
   PubMed Web of Science ®Google Scholar
• Ruprecht RM. Passive immunization with human neutralizing monoclonal antibodies against HIV-1 in macaque models: experimental approaches. Methods Mol. Biol.525, 559–566, xiv (2009).
   PubMedGoogle Scholar
• McElrath MJ, De Rosa SC, Moodie Z et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet372(9653), 1894–1905 (2008).
   PubMed Web of Science ®Google Scholar
• Sandler NG, Wand H, Roque A et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J. Infect. Dis.203(6), 780–790 (2011).
   PubMed Web of Science ®Google Scholar
• Douek D. HIV disease progression: immune activation, microbes, and a leaky gut. Top HIV Med.15(4), 114–117 (2007).
   PubMedGoogle Scholar
• Kosmrlj A, Read EL, Qi Y et al. Effects of thymic selection of the T-cell repertoire on HLA Class 1-associated control of HIV infection. Nature465(7296), 350–354 (2010).
   PubMedGoogle Scholar
• Jennes W, Evertse D, Borget MY et al. Suppressed cellular alloimmune responses in HIV-exposed seronegative female sex workers. Clin. Exp. Immunol.143(3), 435–444 (2006).
   PubMedGoogle Scholar
• Koning FA, Otto SA, Hazenberg MD et al. Low-level CD4+ T cell activation is associated with low susceptibility to HIV-1 infection. J. Immunol.175(9), 6117–6122 (2005).
   PubMed Web of Science ®Google Scholar
• Card CM, McLaren PJ, Wachihi C, Kimani J, Plummer FA, Fowke KR. Decreased immune activation in resistance to HIV-1 infection is associated with an elevated frequency of CD4(+)CD25(+)FOXP3(+) regulatory T cells. J. Infect. Dis.199(9), 1318–1322 (2009).
   PubMedGoogle Scholar
• McLaren PJ, Ball TB, Wachihi C et al. HIV-exposed seronegative commercial sex workers show a quiescent phenotype in the CD4+ T cell compartment and reduced expression of HIV-dependent host factors. J. Infect. Dis.202(Suppl. 3), S339–S344 (2010).
   Google Scholar
• Begaud E, Chartier L, Marechal V et al. Reduced CD4 T cell activation and in vitro susceptibility to HIV-1 infection in exposed uninfected Central Africans. Retrovirology3, 35 (2006).
   PubMedGoogle Scholar
• Kollmann TR, Pettoello-Mantovani M, Katopodis NF et al. Inhibition of acute in vivo human immunodeficiency virus infection by human interleukin 10 treatment of SCID mice implanted with human fetal thymus and liver. Proc. Natl Acad. Sci. USA93(7), 3126–3131 (1996).
   PubMedGoogle Scholar
• Naicker DD, Wang B, Losina E et al. Association of IL-10-promoter genetic variants with the rate of CD4 T-cell loss, IL-10 plasma levels, and breadth of cytotoxic T-cell lymphocyte response during chronic HIV-1 infection. Clin. Infect. Dis.54(2), 294–302 (2011).
   PubMedGoogle Scholar
• Erikstrup C, Kallestrup P, Zinyama-Gutsire RB et al. Reduced mortality and CD4 cell loss among carriers of the interleukin-10–1082G allele in a Zimbabwean cohort of HIV-1-infected adults. AIDS21(17), 2283–2291 (2007).
   PubMed Web of Science ®Google Scholar
• Than S, Hu R, Oyaizu N et al. Cytokine pattern in relation to disease progression in human immunodeficiency virus-infected children. J. Infect. Dis.175(1), 47–56 (1997).
   PubMed Web of Science ®Google Scholar
• Li Q, Estes JD, Schlievert PM et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature458(7241), 1034–1038 (2009).
   PubMed Web of Science ®Google Scholar
• Onanga R, Kornfeld C, Pandrea I et al. High levels of viral replication contrast with only transient changes in CD4(+) and CD8(+) cell numbers during the early phase of experimental infection with simian immunodeficiency virus SIVmnd-1 in Mandrillus sphinx. J. Virol.76(20), 10256–10263 (2002).
   PubMedGoogle Scholar
• Silvestri G, Sodora DL, Koup RA et al. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity18(3), 441–452 (2003).
   PubMed Web of Science ®Google Scholar
• Chakrabarti LA. The paradox of simian immunodeficiency virus infection in sooty mangabeys: active viral replication without disease progression. Front. Biosci.9, 521–539 (2004).
   PubMedGoogle Scholar
• Kornfeld C, Ploquin MJ, Pandrea I et al. Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS. J. Clin. Invest.115(4), 1082–1091 (2005).
   PubMed Web of Science ®Google Scholar
• Jacquelin B, Mayau V, Targat B et al. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled Type 1 IFN response. J. Clin. Invest.119(12), 3544–3555 (2009).
   PubMedGoogle Scholar
• Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat. Rev. Immunol.3(3), 253–257 (2003).
   PubMed Web of Science ®Google Scholar
• Legrand FA, Nixon DF, Loo CP et al. Strong HIV-1-specific T cell responses in HIV-1-exposed uninfected infants and neonates revealed after regulatory T cell removal. PLoS One1, e102 (2006).
   Web of Science ®Google Scholar
• Chase AJ, Yang HC, Zhang H, Blankson JN, Siliciano RF. Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus Type 1-infected elite suppressors correlates with low CD4+ T-cell activation. J. Virol.82(17), 8307–8315 (2008).
   PubMed Web of Science ®Google Scholar
• Jiang Q, Zhang L, Wang R et al. FoxP3+CD4+ regulatory T cells play an important role in acute HIV-1 infection in humanized Rag2-/-γC-/- mice in vivo. Blood112(7), 2858–2868 (2008).
   PubMed Web of Science ®Google Scholar
• Nilsson J, Boasso A, Velilla PA et al. HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood108(12), 3808–3817 (2006).
   PubMed Web of Science ®Google Scholar
• Eggena MP, Barugahare B, Jones N et al. Depletion of regulatory T cells in HIV infection is associated with immune activation. J. Immunol.174(7), 4407–4414 (2005).
   PubMed Web of Science ®Google Scholar
• Battaglia M, Roncarolo MG. The fate of human Treg cells. Immunity30(6), 763–765 (2009).
   PubMed Web of Science ®Google Scholar
• Monteiro P, Gosselin A, Wacleche VS et al. Memory CCR6+CD4+ T cells are preferential targets for productive HIV Type 1 infection regardless of their expression of integrin β7. J. Immunol.186(8), 4618–4630 (2011).
   PubMedGoogle Scholar
• Dunham RM, Cervasi B, Brenchley JM et al. CD127 and CD25 expression defines CD4+ T cell subsets that are differentially depleted during HIV infection. J. Immunol.180(8), 5582–5592 (2008).
   PubMedGoogle Scholar
• Huber S, Gagliani N, Esplugues E et al. Th17 cells express interleukin-10 receptor and are controlled by Foxp3(-) and Foxp3(+) regulatory CD4(+) T cells in an interleukin-10-dependent manner. Immunity34(4), 554–565 (2011).
   PubMed Web of Science ®Google Scholar
• Angel JB, Jacobson MA, Skolnik PR et al. A multicenter, randomized, double-blind, placebo-controlled trial of recombinant human interleukin-10 in HIV-infected subjects. AIDS14(16), 2503–2508 (2000).
   PubMed Web of Science ®Google Scholar
• Weissman D, Ostrowski M, Daucher JA et al. Interleukin-10 decreases HIV plasma viral load: results of a Phase 1 clinical trial. Presented at: 4th Conference Retroviruses Opportunistic Infections January 1997. Washington DC, USA (1997) (Abstract no. 37).
   Google Scholar
• Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J. Exp. Med.205(1), 7–12 (2008).
   PubMed Web of Science ®Google Scholar
• Sato K, Yamashita N, Baba M, Matsuyama T. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity18(3), 367–379 (2003).
   PubMed Web of Science ®Google Scholar
• Sato K, Yamashita N, Baba M, Matsuyama T. Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells. Blood101(9), 3581–3589 (2003).
   PubMed Web of Science ®Google Scholar
• Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting Type 1 regulatory T cells in rodents and humans. Immunol. Rev.212, 28–50 (2006).
   PubMed Web of Science ®Google Scholar
• Coon B, An LL, Whitton JL, von Herrath MG. DNA immunization to prevent autoimmune diabetes. J. Clin. Invest.104(2), 189–194 (1999).
   PubMed Web of Science ®Google Scholar
• Bento CA, Hygino J, Andrade RM et al. IL-10-secreting T cells from HIV-infected pregnant women downregulate HIV-1 replication: effect enhanced by antiretroviral treatment. AIDS23(1), 9–18 (2009).
   PubMedGoogle Scholar
• Moreno-Fernandez ME, Rueda CM, Rusie LK, Chougnet CA. Regulatory T cells control HIV replication in activated T cells through a cAMP-dependent mechanism. Blood117(20), 5372–5380 (2011).
   PubMedGoogle Scholar
• Favre D, Lederer S, Kanwar B et al. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog.5(2), e1000295 (2009).
   PubMed Web of Science ®Google Scholar
• Kanwar B, Favre D, McCune JM. Th17 and regulatory T cells: implications for AIDS pathogenesis. Curr. Opin. HIV AIDS5(2), 151–157 (2010).
   PubMed Web of Science ®Google Scholar
• Aandahl EM, Michaelsson J, Moretto WJ, Hecht FM, Nixon DF. Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J. Virol.78(5), 2454–2459 (2004).
   PubMed Web of Science ®Google Scholar
• Weiss L, Donkova-Petrini V, Caccavelli L, Balbo M, Carbonneil C, Levy Y. Human immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood104(10), 3249–3256 (2004).
   PubMedGoogle Scholar
• Roncarolo MG, Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat. Rev. Immunol.7(8), 585–598 (2007).
   PubMed Web of Science ®Google Scholar